|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar
|
|
2
|
Kerbel RS: Tumor angiogenesis: past,
present and the near future. Carcinogenesis. 21:505–515. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shojaei F: Anti-angiogenesis therapy in
cancer: current challenges and future perspectives. Cancer Lett.
320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo RP, Zhong C, Shi M, et al: Clinical
value of apoptosis and angiogenesis factors in estimating the
prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol.
132:547–555. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iavarone M, Lampertico P, Iannuzzi F, et
al: Increased expression of vascular endothelial growth factor in
small hepatocellular carcinoma. J Viral Hepat. 14:133–139. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dufour JF: Anti-angiogenic therapy for
HCC. Minerva Gastroenterol Dietol. 58:81–86. 2012.PubMed/NCBI
|
|
7
|
Li CY, Shan S, Huang Q, et al: Initial
stages of tumor cell-induced angiogenesis: evaluation via skin
window chambers in rodent models. J Natl Cancer Inst. 92:143–147.
2000. View Article : Google Scholar
|
|
8
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar
|
|
9
|
Bergers G, Javaherian K, Lo KM, Folkman J
and Hanahan D: Effects of angiogenesis inhibitors on multistage
carcinogenesis in mice. Science. 284:808–812. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brandvold KA, Neiman P and Ruddell A:
Angiogenesis is an early event in the generation of myc-induced
lymphomas. Oncogene. 19:2780–2785. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshiji H, Kuriyama S, Yoshii J, et al:
Halting the interaction between vascular endothelial growth factor
and its receptors attenuates liver carcinogenesis in mice.
Hepatology. 39:1517–1524. 2004. View Article : Google Scholar
|
|
12
|
Frachon S, Gouysse G, Dumorti J, et al:
Endothelial cell marker expression in dysplastic lesions of the
liver: an immunohistochemical study. J Hepatol. 34:850–857. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kahn CR: Insulin resistance, insulin
insensitivity, and insulin unresponsiveness: a necessary
distinction. Metabolism. 27:1893–1902. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davila JA, Morgan RO, Shaib Y, McGlynn KA
and El-Serag HB: Diabetes increases the risk of hepatocellular
carcinoma in the United States: a population based case control
study. Gut. 54:533–539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Serag HB, Tran T and Everhart JE:
Diabetes increases the risk of chronic liver disease and
hepatocellular carcinoma. Gastroenterology. 126:460–468. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shintani Y, Fujie H, Miyoshi H, et al:
Hepatitis C virus infection and diabetes: direct involvement of the
virus in the development of insulin resistance. Gastroenterology.
126:840–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Habu D, Shiomi S, Tamori A, et al: Role of
vitamin K2 in the development of hepatocellular carcinoma in women
with viral cirrhosis of the liver. JAMA. 292:358–361. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bugianesi E, McCullough AJ and Marchesini
G: Insulin resistance: a metabolic pathway to chronic liver
disease. Hepatology. 42:987–1000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marchesini G, Bianchi G, Merli M, et al:
Nutritional supplementation with branched-chain amino acids in
advanced cirrhosis: a double-blind, randomized trial.
Gastroenterology. 124:1792–1801. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muto Y, Sato S, Watanabe A, et al: Effects
of oral branched-chain amino acid granules on event-free survival
in patients with liver cirrhosis. Clin Gastroenterol Hepatol.
3:705–713. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muto Y, Sato S, Watanabe A, et al:
Overweight and obesity increase the risk for liver cancer in
patients with liver cirrhosis and long-term oral supplementation
with branched-chain amino acid granules inhibits liver
carcinogenesis in heavier patients with liver cirrhosis. Hepatol
Res. 35:204–214. 2006.PubMed/NCBI
|
|
22
|
Nishitani S, Ijichi C, Takehana K,
Fujitani S and Sonaka I: Pharmacological activities of
branched-chain amino acids: specificity of tissue and signal
transduction. Biochem Biophys Res Commun. 313:387–389. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishitani S, Takehana K, Fujitani S and
Sonaka I: Branched-chain amino acids improve glucose metabolism in
rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol.
288:G1292–G1300. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kawaguchi T, Taniguchi E, Itou M, et al:
Branched-chain amino acids improve insulin resistance in patients
with hepatitis C virus-related liver disease: report of two cases.
Liver Int. 27:1287–1292. 2007.PubMed/NCBI
|
|
25
|
Kawaguchi T, Nagao Y, Matsuoka H, Ide T
and Sata M: Branched-chain amino acid-enriched supplementation
improves insulin resistance in patients with chronic liver disease.
Int J Mol Med. 22:105–112. 2008.PubMed/NCBI
|
|
26
|
Kaji K, Yoshiji H, Kitade M, et al: Impact
of insulin resistance on the progression of chronic liver diseases.
Int J Mol Med. 22:801–808. 2008.PubMed/NCBI
|
|
27
|
Yoshiji H, Noguchi R, Kitade M, et al:
Branched-chain amino acids suppress insulin-resistance-based
hepatocarcinogenesis in obese diabetic rats. J Gastroenterol.
44:483–491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsuchiya K, Asahina Y, Sato T, et al: Oral
supplementation with branched-chain amino acid (BCAA) improves
survival and decreases the third time recurrence after successful
treatment of hepatocellular carcinoma (HCC). J Hepatol (EASL
proceeding). (48 suppl)2:S1602009.
|
|
29
|
Yoshiji H, Noguchi R, Toyohara M, et al:
Combination of vitamin K2 and angiotensin-converting enzyme
inhibitor ameliorates cumulative recurrence of hepatocellular
carcinoma. J Hepatol. 51:315–321. 2009. View Article : Google Scholar
|
|
30
|
Bruix J and Sherman M: Management of
hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005.
View Article : Google Scholar
|
|
31
|
Bruix J and Sherman M: Diagnosis of small
HCC. Gastroenterology. 129:13642005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fartoux L, Poujol-Robert A, Guéchot J,
Wendum D, Poupon R and Serfaty L: Insulin resistance is a cause of
steatosis and fibrosis progression in chronic hepatitis C. Gut.
54:1003–1008. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferrara N: VEGF as a therapeutic target in
cancer. Oncology. 69:11–16. 2005. View Article : Google Scholar
|
|
34
|
Yoshiji H, Noguchi R, Ikenaka Y, et al:
Combination of branched-chain amino acids and
angiotensin-converting enzyme inhibitor suppresses the cumulative
recurrence of hepatocellular carcinoma: a randomized control trial.
Oncol Rep. 26:1547–1553. 2011.
|
|
35
|
Kaji K, Yoshiji H, Ikenaka Y, et al:
Possible involvement of angiogenesis in chronic liver diseases:
interaction among renin-angiotensin-aldosterone system, insulin
resistance and oxidative stress. Curr Med Chem. 19:1889–1898. 2012.
View Article : Google Scholar
|
|
36
|
Hagiwara A, Nishiyama M and Ishizaki S:
Branched-chain amino acids prevent insulin-induced hepatic tumor
cell proliferation by inducing apoptosis through mTORC1 and
mTORC2-dependent mechanisms. J Cell Physiol. 227:2097–2105. 2012.
View Article : Google Scholar
|
|
37
|
Kawaguchi T, Izumi N, Charlton MR and Sata
M: Branched-chain amino acids as pharmacological nutrients in
chronic liver disease. Hepatology. 54:1063–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shimizu M, Kubota M, Tanaka T and Moriwaki
H: Nutraceutical approach for preventing obesity-related colorectal
and liver carcinogenesis. Int J Mol Sci. 13:579–595. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoshiji H, Noguchi R, Kaji K, et al:
Attenuation of insulin-resistance-based hepatocarcinogenesis and
angiogenesis by combined treatment with branched-chain amino acids
and angiotensin-converting enzyme inhibitor in obese diabetic rats.
J Gastroenterol. 45:443–450. 2010. View Article : Google Scholar
|
|
40
|
Miuma S, Ichikawa T, Arima K, et al:
Branched-chain amino acid deficiency stabilizes insulin-induced
vascular endothelial growth factor mRNA in hepatocellular carcinoma
cells. J Cell Biochem. 113:3113–3121. 2012. View Article : Google Scholar
|
|
41
|
Yoshiji H, Kuriyama S, Yoshii J, et al:
Synergistic effect of basic fibroblast growth factor and vascular
endothelial growth factor in murine hepatocellular carcinoma.
Hepatology. 35:834–842. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wierzbowska A, Robak T, Wrzesień-Kuś A,
Krawczyńska A, Lech-Marańda E and Urbańska-Ryś H: Circulating VEGF
and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with
acute leukemia. Eur Cytokine Netw. 14:149–153. 2003.PubMed/NCBI
|
|
43
|
Deprimo SE, Bello CL, Smeraglia J, et al:
Circulating protein biomarkers of pharmacodynamic activity of
sunitinib in patients with metastatic renal cell carcinoma:
modulation of VEGF and VEGF-related proteins. J Transl Med.
5:322007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nagaoka S, Yoshida T, Akiyoshi J, et al:
The ratio of serum placenta growth factor to soluble vascular
endothelial growth factor receptor-1 predicts the prognosis of
hepatocellular carcinoma. Oncol Rep. 23:1647–1654. 2010.
|
